{"publication_id":"9fd402e5-02e8-4ac2-acd2-1c6bf571b6e5","content_hash":"sha256:3d351474d9c705801cde52a71f56fde8b9f14cfab53c5e6b600623658d918685","nodes":[{"id":"9fd402e5-02e8-4ac2-acd2-1c6bf571b6e5","type":"publication","title":"fisetin: receipt-backed evidence fronts"},{"id":"claim_1","type":"claim","text":"What evidence fronts does fisetin occupy across animal model, cell or in-vitro model, and chemistry/formulation, and what remains untested?"},{"id":"claim_2","type":"claim","text":"Finding: DHC and fisetin caused dose-dependent reduction in viability and increase in apoptosis in PC3 cells at 72 h."},{"id":"claim_3","type":"claim","text":"Answer: this 5-source primary bundle supports a receipt-backed scoping note for fisetin, spanning 2010-2023. The source facts cover 5 population context(s) and 5 intervention/exposure context(s). The bounded signal is context separation across animal model, cell or in-vitro model, and chemistry/formulation: the bundle identifies what has been measured and where the evidence separates, without establishing a causal, clinical, species-translated, or mechanistically integrated intervention claim. Representative source-extracted findings include: IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells; a 2.5-fold increase of fisetin solubility was achieved for FisNam; Fisetin (<20 µM) restored cell viability and repressed apoptosis, autophagy and ROS production in Tm-treated cells."},{"id":"claim_4","type":"claim","text":"The selected receipts group because each carries a fact-level extraction for fisetin; they separate by context (animal model, cell or in-vitro model, and chemistry/formulation), so they are not interchangeable evidence for one endpoint."},{"id":"claim_5","type":"claim","text":"Source-literature boundary for fisetin: the listed sources define separate evidence fronts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources."},{"id":"source_1","type":"source","study":"Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence","year":2023,"doi":"10.1111/acel.14060","url":"https://pubmed.ncbi.nlm.nih.gov/38062873/","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Improving solubility of fisetin by cocrystallization","year":2014,"doi":"10.1039/c4ce01713g","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Fisetin Protects PC12 Cells from Tunicamycin-Mediated Cell Death via Reactive Oxygen Species Scavenging and Modulation of Nrf2-Driven Gene Expression, SIRT1 and MAPK Signaling in PC12 Cells","year":2017,"doi":"10.3390/ijms18040852","url":"https://pubmed.ncbi.nlm.nih.gov/28420170/","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Antiproliferative Mechanisms of the Flavonoids 2,2′-Dihydroxychalcone and Fisetin in Human Prostate Cancer Cells","year":2010,"doi":"10.1080/01635581003605524","url":"https://pubmed.ncbi.nlm.nih.gov/20574928/","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Senolytic elimination of senescent macrophages restores muscle stem cell function in severely dystrophic muscle","year":2022,"doi":"10.18632/aging.204275","url":"https://pubmed.ncbi.nlm.nih.gov/36084954/","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"9fd402e5-02e8-4ac2-acd2-1c6bf571b6e5","to":"claim_1","type":"contains_claim"},{"from":"9fd402e5-02e8-4ac2-acd2-1c6bf571b6e5","to":"claim_2","type":"contains_claim"},{"from":"9fd402e5-02e8-4ac2-acd2-1c6bf571b6e5","to":"claim_3","type":"contains_claim"},{"from":"9fd402e5-02e8-4ac2-acd2-1c6bf571b6e5","to":"claim_4","type":"contains_claim"},{"from":"9fd402e5-02e8-4ac2-acd2-1c6bf571b6e5","to":"claim_5","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}